Memphasys achieves clinical trial milestone

Memphasys (ASX:MEM), an Australian reproductive biotechnology company, has successfully completed the clinical registration study for its Felix™ System. This innovative sperm selection technology aims to improve assisted reproductive technology (ART) procedures. The study's completion is a major milestone that will assist Memphasys in advancing its commercial strategy.

Memphasys sets sights on global market expansion

Memphasys has completed the clinical trial for its Felix™ System, marking a significant step towards enhancing assisted reproductive technology procedures. The study, conducted in collaboration with Monash IVF Group, is expected to validate the system's safety and efficacy, supporting regulatory submissions in Europe, Australia, and India. Memphasys aims to accelerate its commercial strategy by leveraging trial results to engage in partnerships and expand market access. The company is focused on global expansion, targeting markets in Europe, UAE, India, and more, supported by strategic alliances and existing distribution agreements. Memphasys' ambition is to lead the ART market with its superior sperm selection technology.

Executive insights on Felix™ System's progress

The completion of this trial is a transformative milestone for Memphasys and a testament to the dedication of our team, stakeholders, and shareholders. We are excited by the prospect of the Felix™ System being the first novel sperm separation device in the market, following CE Mark registration.